CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedVH
Venrock Healthcare Capital Partners
Activity from announced rounds
Activity in this selectioneast-x-ventures-bd7f0fff
- Rounds participated in
- 3
- Confirmed lead rounds
- — 3 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $645M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionKorsana Biosciences
Develops novel therapies to reduce the burden of neurodegenerative diseases
$175MSeries A
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosed